Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

NCT05382728 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

680

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC
EGFR Activating Mutation

Interventions

DRUG: TY-9591
DRUG: placebo Osimertinib
DRUG: Osimertinib
DRUG: placebo TY-9591

Sponsor

TYK Medicines, Inc